soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Presented at ACC.25: Among participants with type 2 diabetes and disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo soul trial oral semaglutide cardiovascular

The semaglutide weight management drug market remained anchored to hospital-linked dispensing because initiation often occurred under endocrinology, cardiology, or primary care supervision, especially when comorbid obesity, diabetes, and cardiovascular risk had to be managed together

Losing some bone and muscle mass is inevitable any time a person loses significant weight

The explanation and personalized approach made all the difference. Rosanna Savarino June 2026 Excellent service and wonderful attention

Mechanism of Action To understand how semaglutide works, its helpful to know a bit about how the body controls blood sugar